Difference in proangiogenic potential of systemic and pulmonary endothelium: role of CXCR2

Aigul Moldobaeva1, Elizabeth M. Wagner2
1Department of Medicine, Johns Hopkins University, Baltimore, Md., USA.
2Department of Medicine, Johns Hopkins University, Baltimore, Maryland

Tóm tắt

The systemic vasculature in and surrounding the lung is proangiogenic, whereas the pulmonary vasculature rarely participates in neovascularization. We studied the effects of the proangiogenic ELR+ CXC chemokine MIP-2 (macrophage inflammatory protein-2) on endothelial cell proliferation and chemotaxis. Mouse aortic, pulmonary arterial, and lung microvascular endothelial cells were isolated and subcultured. Proliferation ([3H]thymidine uptake) and migration (Transwell chemotaxis) were evaluated in each cell type at baseline and upon exposure to MIP-2 (1–100 ng/ml) without and with exposure to hypoxia (24 h)-reoxygenation. Baseline proliferation did not vary among cell types, and all cells showed increased proliferation after MIP-2. Aortic cell chemotaxis increased markedly upon exposure to MIP-2; however, neither pulmonary artery nor lung microvascular endothelial cells responded to this chemokine. Assessment of CXCR2, the G protein-coupled receptor through which MIP-2 signals, displayed no baseline difference in mRNA, protein, or cell surface expression among cell types. Exposure to hypoxia increased expression of CXCR2of aortic endothelial cells only. Additionally, aortic cells, compared with pulmonary cells, showed significantly greater protein and activity of cathepsin S, a proteolytic enzyme important for cell motility. Thus the combined effects of increased cathepsin S activity, providing increased motility and enhanced CXCR2expression after hypoxia, both contribute to the proangiogenic phenotype of systemic arterial endothelial cells.

Từ khóa


Tài liệu tham khảo

10.4049/jimmunol.165.9.5269

10.1172/JCI3145

10.1152/jappl.1997.82.1.284

10.1016/0167-4838(96)00038-6

10.1136/hrt.78.2.171

10.1164/ajrccm.157.4.9707063

10.1016/j.mvr.2004.02.002

10.1158/0008-5472.CAN-04-1243

10.1016/S1359-6101(01)00014-4

10.1016/S1535-6108(04)00111-4

10.1084/jem.18.5.507

Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, and Strieter RM.Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis.J Immunol162: 5511–5518, 1999.

10.1159/000058728

10.1126/science.1281554

10.1038/sj.onc.1207616

10.1007/978-1-4615-4863-8_35

10.4049/jimmunol.170.6.3369

10.1016/S0891-5849(02)01005-5

10.1097/00005382-198710000-00005

10.1016/S0002-9440(10)64521-X

10.1006/cyto.1998.0465

10.1096/fj.99-0963com

10.1084/jem.20030267

10.1161/01.RES.0000060485.20318.96

10.1165/rcmb.2002-0276OC

Stevens T, Rosenberg R, Aird W, Quertermous T, Johnson FL, Garcia JG, Hebbel RP, Tuder RM, and Garfinkel S.NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases.Am J Physiol Cell Physiol281: C1422–C1433, 2001.

10.1074/jbc.270.45.27348

10.1016/S0014-4835(03)00115-5

10.1016/S0002-9440(10)65654-4

10.1136/thx.18.3.225

10.1161/01.RES.0000070112.80711.3D

10.1161/01.RES.8.2.353